Live Analyst Rating Changes 1941 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jason Zemansky
BofA
Jason Zemansky
Bank of America Securities
Wall Street Analyst
★★★★☆
#616
on 13Foresight · ranked by our own returns
47%
Success Rate
+7.8%
Average Return
14 of 30 calls profitable · +6.2% vs benchmark
📈 Across the calls we could measure, roughly 47% of Jason Zemansky's ratings turned a profit when each position was held for 1 year — averaging +7.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

112 Buy 48 Hold 16 Sell
Jason's Stock Coverage 23 ratings · 2026-06-23
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
CYTK
Cytokinetics
 Jun 16, 2026 HOLD Strong Buy
+8.2% avg upside
36 analysts
$83.00
4.85% Upside
 +5.0%
ABOS
Acumen Pharmaceuticals
 Jun 11, 2026 BUY Strong Buy
+241.1% avg upside
10 analysts
$8.00
233.38% Upside
 ·
BBIO
BridgeBio Pharma
 Jun 11, 2026 BUY Strong Buy
+35.5% avg upside
34 analysts
$101.00
46.50% Upside
 -1.9%
INSM
Insmed
 Jun 11, 2026 BUY Strong Buy
+78.6% avg upside
36 analysts
$214.00
117.12% Upside
 +1.8%
RCKT
Rocket Pharmaceuticals
 Jun 11, 2026 BUY Buy
+381.9% avg upside
29 analysts
$10.00
188.96% Upside
 ·
MDGL
Madrigal Pharmaceuticals
 Jun 11, 2026 HOLD Strong Buy
-6.7% avg upside
31 analysts
$542.00
5.58% Upside
 +6.6%
TYRA
Tyra Bioscience
 Jun 10, 2026 BUY Strong Buy
+50.9% avg upside
17 analysts
$42.00
39.25% Upside
 +14.4%
KURA
Kura Oncology
 Jun 03, 2026 BUY Strong Buy
+155.2% avg upside
26 analysts
$30.00
189.48% Upside
 +10.6%
TVTX
Travere Therapeutics
 Jun 03, 2026 BUY Strong Buy
-15.7% avg upside
22 analysts
$59.00
7.08% Upside
 +15.1%
KROS
Keros Therapeutics
 Jun 03, 2026 HOLD Strong Buy
+133.4% avg upside
21 analysts
$20.00
82.14% Upside
 ·
IKT
Inhibikase Therapeutics
 Jun 03, 2026 BUY Strong Buy
+226.4% avg upside
8 analysts
$6.00
226.10% Upside
 ·
LYEL
Lyell Immunopharma
 Jun 03, 2026 SELL Buy
+103.3% avg upside
10 analysts
$12.00
0.35% Upside
 +4.8%
EIKN
Eikon Therapeutics, Inc.
 Jun 03, 2026 BUY Strong Buy
+146.9% avg upside
5 analysts
$32.00
232.74% Upside
 ·
LGND
Ligand Pharma
 Jun 02, 2026 BUY Strong Buy
-13.3% avg upside
15 analysts
$266.00
1.45% Upside
 +18.1%
SNDX
Syndax Pharmaceuticals
 May 21, 2026 BUY Strong Buy
+86.7% avg upside
27 analysts
$29.00
50.01% Upside
 -3.7%
BIIB
Biogen
 May 14, 2026 HOLD Buy
+23.7% avg upside
51 analysts
$203.00
1.63% Upside
 +4.4%
RCUS
Arcus Biosciences
 Apr 21, 2026 HOLD Strong Buy
+27.7% avg upside
20 analysts
$25.00
8.14% Downside
 -1.6%
ESPR
Esperion
 Mar 30, 2026 SELL Buy
+699.5% avg upside
22 analysts
$1.78
43.74% Downside
 -19.8%
HOWL
Werewolf Therapeutics
 Feb 17, 2026 BUY Strong Buy
+1778.9% avg upside
8 analysts
$7.00
1791.41% Upside
 -45.2%
BMRN
BioMarin Pharmaceutical
 Oct 30, 2024 BUY Strong Buy
+70.1% avg upside
52 analysts
 — -22.1%
OKUR
OnKure Therapeutics
 Mar 28, 2024 SELL Buy
+432.1% avg upside
12 analysts
$12.00
170.18% Upside
 +73.1%
KLRS
Kalaris Therapeutics
 Dec 26, 2023 SELL Buy
+185.9% avg upside
13 analysts
$1.00
77.32% Downside
 +37.0%
QTTB
Q32 Bio
 Nov 17, 2023 HOLD Buy
+331.9% avg upside
24 analysts
 — +226.9%
🔒 18 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jason Zemansky — Frequently Asked Questions
How accurate are Jason Zemansky's stock ratings?
Based on the calls 13Foresight could measure, about 47% of Jason's ratings were profitable over a one-year hold, with an average return of +7.8% per rating, or +6.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Jason ranked on 13Foresight?
Jason Zemansky is currently ranked #616 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jason cover?
Jason most recently has ratings on CYTK, ABOS, BBIO, INSM, RCKT, MDGL, TYRA, KURA, TVTX, KROS, IKT, LYEL and 11 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.